<DOC>
	<DOCNO>NCT00180258</DOCNO>
	<brief_summary>The purpose study determine whether combined mortality hospitalization heart failure patient receive optimal pharmacologic therapy reduce combine optimal pharmacologic therapy 1 ) biventricular pace therapy alone 2 ) biventricular pace defibrillation .</brief_summary>
	<brief_title>Comparison Medical Therapy , Pacing Defibrillation Heart Failure</brief_title>
	<detailed_description>Evaluation new therapy treatment heart failure address mortality , morbidity , hospitalization , cardiac symptom function compare standard pharmacologic therapy . The COMPANION trial design address objective . This clinical investigation open-label , prospective , multi-center , randomized clinical trial . Every patient enrol study prescribe optimal pharmacologic heart failure therapy , tolerate , regardless randomization .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Moderate severe heart failure , define symptomatic heart failure least six month NYHA Class III IV symptom time enrollment , AND least one follow event previous 12 month : Hospitalization heart failure management Outpatient visit intravenous ( IV ) inotropes vasoactive infusion administer continuously least 4 hour Emergency room visit least twelve hour duration IV heart failure medication administer ( include diuretic ) QRS &gt; = 120 m PR interval &gt; 150 m two lead 12lead ECG Left ventricular ejection fraction &lt; = 35 % Left ventricular end diastolic dimension &gt; = 60 mm ( require LVEF measure echo ) &gt; 3.0 cm/m2 [ The cm/m2 calculate LVEDD ( cm ) divide BSA ( body surface area ) ] . Age &gt; = 18 year Optimal pharmacologic therapy heart failure Unable unwilling undergo device implant followup test Meet general indication implantable cardioverter defibrillator Meet general indication antibradycardia pace Expected receive heart transplant next six month Chronic , medically refractory atrial tachyarrhythmias Unexplained syncope Myocardial infarction within 60 day randomization History noncompliance oral heart failure therapy Progressive unstable angina Uncontrolled blood pressure : Systolic BP &gt; 160 mm Hg &lt; 85 mm Hg diastolic BP &gt; 90 mm Hg Patients hypersensitivity 0.7 mg nominal dose dexamethasone acetate Surgically uncorrected primary valvular heart disease Coronary artery disease ( CAD ) surgical percutaneous correction recent ( within 60 day randomization ) Women pregnant use medically acceptable birth control Hypertrophic obstructive cardiomyopathy Amyloid disease Hospitalization heart failure IV inotropic vasoactive therapy excess 4 hour 30 day prior enrollment Have tricuspid prosthesis Involved investigational study Life expectancy &lt; 6 month due medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Cardiac Resynchronization Therapy ( CRT )</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Defibrillator</keyword>
	<keyword>Pacemaker</keyword>
</DOC>